Gastroenterology Research and Practice / 2017 / Article / Tab 3 / Research Article
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression Table 3 Prognostic factors for overall survival based on univariate and multivariate analyses.
Variables Univariate analysis Multivariate analysis value valueHR 95% CI Age ≥75 years 0.852 <75 years Sex Male 0.518 Female Cause HCV 0.711 Others Child-Pugh class A 0.276 B BCLC stage B 0.154 C AST (U/L) <80 0.924 ≥80 ALT (U/L) <80 0.834 ≥80 Total bilirubin (mg/dL) <1.0 0.843 ≥1.0 Albumin (g/dL) <3.6 0.149 ≥3.6 AFP (ng/mL) ≥400 0.026 0.971 0.990 0.568–1.726 <400 DCP (mAU/mL) ≥400 <0.001 <0.001 3.443 1.818–6.520 <400 Best overall response PR+SD 0.052 PD Subsequent or additional treatment Yes 0.026 0.013 0.499 0.288–0.865 No Progression of macrovascular invasion Yes <0.001 0.003 2.974 1.453–6.088 No Intrahepatic growth Yes 0.577 No Extrahepatic growth Yes 0.376 No New intrahepatic lesion Yes 0.071 No New extrahepatic lesion Yes 0.569 No Treatment duration before PD (months) ≥3 0.008 0.321 0.757 0.436–1.313 <3 Sorafenib continuation after PD Yes 0.048 0.969 0.989 0.576–1.700 No
HCV: hepatitis C virus; BCLC: Barcelona clinic liver cancer; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AFP: alpha-fetoprotein; DCP: des-gamma carboxy-prothrombin; PR: partial response; SD: stable disease; PD: progressive disease.